Effectiveness of Simvastatin Versus Gemfibrozil for Primary Prevention of Cardiovascular Events: A Retrospective Cohort Study of 223,699 Primary Care Patients
ConclusionThe results of this study showed better population-level effectiveness of simvastatin compared with gemfibrozil for the primary prevention of MACE; however, a definitive randomized controlled trial is required to compare simvastatin with gemfibrozil among patients with low HDL cholesterol, as they appear to obtain benefit with gemfibrozil.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Coronary Heart Disease | Drugs & Pharmacology | Electronic Health Records (EHR) | Gemfibrozil | Heart | Heart Disease | Hong Kong Health | Primary Care | Simvastatin | Statin Therapy | Stroke | Study | Women | Zocor